New drug combo aims to supercharge immune therapy for lung cancer patients
Disease control
Completed
This early-phase study tested whether adding the drug copanlisib to the standard immune therapy durvalumab is safe and can help overcome resistance in people with stage III non-small cell lung cancer that cannot be removed by surgery. Eleven participants who had already received …
Phase: PHASE1 • Sponsor: Zhonglin Hao • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC